it has actually been with us for some time. For years, morphologists have been pointing out that, besides the fibrosis and cystic lesions that characterise the late stages of these diseases, early on there are accumulations of macrophages, lymphocytes and often, polymorphonuclear leucocytes. An excellent example of this is idiopathic pulmonary fibrosis (IPF), a disease for which Scadding championed the term "fibrosing alveolitis", perceptively implying that not only is this disease characterised by fibrosis, but it is an alveolitis that causes the fibrosis and hence, the derangements of the alveolar structures." 12 There is compelling morphological evidence that the alveolitis precedes the derangements to the alveolar structures that characterise interstitial disease. In 19 There is also ample evidence that an alveolitis is the earliest manifestation of IPF.3 82021 Probably the most convincing data come from the studies of Carrington and Gaensler who have shown that patients with morphological evidence of desquamative interstitial pneumonitis (early 1PF) are those who can resolve completely.20 Conversely, those with usual interstitial pneumonitis (late IPF), do not. Alveolitis is also prominent in the descriptions of biopsies of patients with early hypersensitivity pneumonitis (extrinsic allergic alveolitis),22 23 asbestosis,24 silicosis,25 26 and the interstitial lung diseases associated with the collagen vascular disorders. 27 Furthermore, a variety of experimental animal models of interstitial lung disease including asbestosis,28 29 7 The technique is a simple extension of routine fibreoptic bronchoscopy. After local anaesthesia, the fibreoptic bronchoscope is wedged into a distal bronchus, usually in the lingula or right middle lobe (all lobes can be used, but the yield is somewhat greater in these sites). Following the original method developed by Reynolds and colleagues,35 we use a total of 100 ml of 0 9% sterile saline (in five 20 ml aliquots) for each site up to a maximum of three sites -that is, 300 ml total. Each aliquot of saline is flushed through the bronchoscope and immediately aspirated using conventional suction. With this technique, the average volume returned from a normal, non-smoking individual is 50-70% with recovery of 5-10 x 106 cells and 1-10 mg protein. The validity of the "total cell" method, however, depends on the validity of quantifying the total number of cells per standard lavage. The problem is not in counting the total number of cells (this is easily done using routine laboratory methods), but rather in the variability in the volume returned.7 While several series have shown that the average volume returned for groups of patients are similar,32 35 39 there is significant variability (per standard 100 ml lavage) within each group, in the same patient from segment to segment, and in the same segment from day to day.32 The reasons for this have not been studied in detail, but are probably associated with bronchial tone, the site of the equal pressure point relative to the position of the bronchoscope, the force at which the fluid is instilled, the length of time it is left in the distal lung, and the force of the vacuum used for aspiration. Furthermore, the volume returned is dependent on the disease statemuch less is returned from patients with lung destruction that from normal individuals. Because of this problem, the safest approach is to present the data as a cell differential. However, the total cell method may yield important insights into the intensity of the alveolitis and, until enough data are obtained worldwide to establish clear standards, it is worth using both methods.
Quantification of the noncellular constituents of lavage fluid presents even a more difficult problem than quantification of the cellular components. The easiest approach to the 67Ga scan is to simply read it as positive or negative. However, the amount of gallium-67 taken up by the parenchyma can also be quantified by visual or computerised methods. In this context, a "gallium-67 index" can be generated which accounts for the area of lung involved as well as the intensity of each region of uptake.33 For example, assuming the liver to be 4 + and a region of the abdomen to be 0, a 0-4+ "intensity" scale can be constructed for each patient. Thus, if 50% of the lung is involved to an intensity of 3 +, the individual has 3 x 50 or 150 index units. Using such a method, normal individuals have 50 index units or less.
In evaluating 67Ga scans, it is important to distinguish between lung parenchyma and hilar nodes.34 44 While the activity of the hilar nodes may be of interest in disorders such as sarcoidosis, it is the activity in the parenchyma that reflects the alveolitis and hence is relevant to the pathogenesis, staging, and therapy of the interstitial lung diseases.
Inflammatory and immune processes in normal alveolar structures
With the use of bronchoalveolar lavage, a great deal of information has accumulated concerning the effector cells and inflammatory and immune related mediators present in the normal human alveolar structures (see references 1 and 7 for comprehensive reviews). In normal, non-smoking individuals, the alveolar macrophage is the major effector cell present. Importantly, although this histiocytoxis-X,1 32 and asbestosis.7 65 66 While all effector cells comprising the alveolitis undoubtedly play a role in the derangement to the alveolar structures that characterise IPF, the presence of the neutrophil is paramount.5 The neutrophil is a short-lived cell that, within a short time after reaching the lung, releases a potent armamentarium of inflammatory mediators (such as oxidants and connective tissue specific proteases) that can injure parenchymal cells and disorganise the extracellular matrix.7 Furthermore, by virtue of the chronicity of the alveolitis (we have seen patients with IPF in which neutrophils comprise greater that 25 % of all effector cells for over three years), the IPF lung is constantly under attack by effector cells with the potential to significantly derange the alveolar structures. In this context, it is no wonder that, on the average, IPF is the most rapidly progressive of the interstitial disorders.'
Since neutrophils are blood cells not normally found in alveolar structures, there must be a mechanism by which they are chronically attracted to the alveolar structures in diseases like IPF. Interestingly, although the complement system is classically thought to play a role in neutrophil attraction (mostly through CSa, a complement fragment that is chemotactic for neutrophils), there is no evidence that the complement system is involved in the chemotaxis of blood neutrophils in those chronic interstitial lung diseases characterised by a neutrophil alveolitis.9 41 67 In those diseases studied, the source for the neutrophil attraction seems to be the alveolar macrophage, a cell that when appropriately stimulated, releases a chemotactic factor that is relatively specific for neutrophils.68 For some interstitial lung diseases, the stimulus that activates the macrophage to release this chemotactic factor is known. In IPF and familial pulmonary fibrosis the stimulus is locally produced immune complexes produced within the alveolar structures ;58 these complexes activate the macrophage through its IgG Fc receptor.58 68 In asbestosis, the stimulus is the asbestos particle itself;29 when macrophages attempt to ingest the asbestos they are activated to release the neutrophil chemotactic factor.
Thus, the alveolitis of the neutrophil disorders seems to have two components: increased numbers of activated macrophages and large numbers of neutrophils. In this regard, if the alveolitis theory of interstitial lung disease is correct, it is reasonable to hypothesise that individuals with neutrophil disorders that have a high intensity alveolitis (that is, large numbers of activated macrophages and neutrophils) will deteriorate while those with low intensity alveolitis (that is, small numbers of activated macrophils and neutrophils) will not. In IPF, this hypothesis has been substantiated by studies in both Britain and USA. Haslam et a!69 have demonstrated that those with larger proportions of neutrophils clearly do more poorly than those with low numbers of neutrophils. Likewise, Keogh et a170 have shown that over one year, if neutrophils represent greater than 10% of the effector cells present and if the gallium scan is positive (that is, larger numbers of activated macrophages) then 45% of patients with IPF will deteriorate in at least two functional parameters such as vital capacity, total lung capacity, or diffusing capacity. In contrast, with low intensity alveolitis (that is, less than 10% neutrophils or negative gallium scan), less than 10 % of patients will deteriorate.
In addition to predicting deterioration in diseases like IPF, the presence of a neutrophil alveolitis can be used to identify individuals in the earliest stages of their disease. For example, recent studies by Bitterman et al64 have shown that in families with familial pulmonary fibrosis, a neutrophil alveolitis occurs before any evidence of lung dysfunction.
LYMPHOCYTIC DISORDERS
In contrast to the neutrophilic disorders, the alveolitis of the lymphocytic disorders is distinguished by large numbers of macrophages and lymphocytes without neutrophils.7 32 41 Whereas lymphocytes comprise < 10% of the normal effector cell populations in the neutrophilic disorders, lymphocytes represent at least 15 %4, and usually more, of the cells making up the alveolitis of the lymphocytic disorders.32 Moreover, for all those lymphocytic disorders characterised to date, the expanded lymphocyte populations are primarily T lymphocytes.7 41 49 The best characterised lymphocytic disorder is sarcoidosis. 4 The alveolitis of a typical patient includes a five-fold increase in number of macrophages and lymphocytes together with a relatively expanded proportion of T lymphocytes. Thus, a standard 100 ml lavage of a patient with active pulmonary sarcoidosis will contain 60 % macrophages and 40% lymphocytes with T lymphocytes representing 36 % of all cells recovered (normally T cells represent < 7% of all cells recovered). In terms of total cells, assuming that 5 x 107 cells and 60 ml of fluid were recovered, this would represent 500 x 103 macrophages/ml recovered and 300 x 103 T cells/ml recovered. In the context that lavage of a normal individual contains at most 10 x 103 T cells/ml fluid recovered,7 it is obvious, therefore, that sarcoid is clearly a disease characterised by marked expansion of the lung T cell populations. 4 Lung T lymphocytes play a critical role in the pathogenesis of sarcoidosis. Not only is the alveolitis characterised by an increase in number of T cells, but the T cell populations are altered such that there is a relative expansion of the proportions of T helper cells and a decreased proportion of T suppressor cells.48 Of paramount importance, these lung T cell populations are activated and release lymphokines such as monocyte chemotactic factor and migration inhibitory factor.457 Both products are important in granuloma formation. Monocyte chemotactic factor attracts monocytes to the alveolar structures while migration inhibitory factor immobilises the cells and activates them.4 57 Since monocytes are the building blocks of granuloma formation, this explains one important aspect of this disease. In addition, the lung T cells in sarcoidosis are nonspecifically releasing "helper factors" that stimulate lung B cells to produce immunoglobulin in a polyclonal fashion.7' While this may not be important in terms of pathogenesis, it explains to a large extent the mechanisms of the hypergammaglobinaemia of this disease-that is, the increased immunoglobulins found in blood are derived from lung B cells stimulated by lung T cells.
The mechanism of the expansion of T cell numbers and of the state of their activation are not fully understood in sarcoidosis, but the alveolar macrophage seem to play a major role. These patients have markedly positive gallium scans and thus a high density of activated alveolar macrophages. 45 Interestingly, however, the macrophages of the sarcoidosis lung seems to be activated in a fashion different from that in idiopathic pulmonary fibrosis. While IPF macrophages produce neutrophil chemotactic factor,58 sarcoidosis macrophages instead release interleukin-l, a factor that expands the numbers of T cells. 72 Macrophage T cell interactions at sites of disease activity in sarcoidosis may explain the mechanism of increased serum angiotensin converting enzyme in these patients. Recent Two questions are frequently asked in relation to this approach. First, do you need both bronchoalveolar lavage and gallium scanning? Second, if a patient has high intensity alveolitis, is it necessary to start therapy immediately or can you wait to see if the alveolitis will subside spontaneously?
The answer to the first question is-we do not know. For routine clinical practice, the gallium scan is probably the best way to assess the intensity of the activated alveolar macrophages while bronchoalveolar lavage is the best method to assess lymphocytes and neutrophils. Our current data suggest the use of both parameters increases accuracy significantly, but the final answers are not yet in. If the patient has coexisting inflammatory airway disease, (for example, from cigarette smoking) there is no choice-lavage is not as useful as gallium-67 scanning. Likewise, if the patient does not fit the guidelines for bronchoalveolar lavage,37 gallium-67 scanning is the only option. However, in most circumstances, lavage is more sensitive and yields more information. Thus, if only one test can be used, lavage is probably the best choice.
The answer to the second question is not definitively known but guidelines are beginning to emerge, at least for IPF and sarcoidosis. For IPF, the alveolitis is so potent that therapy is usually begun as soon as high intensity alveolitis is detected. For sarcoidosis, high intensity alveolitis is almost invariably followed by a deterioration in at least one functional parameter over the subsequent six months. It is not clear, however, what happens in the long term. For now, therefore, we usually observe such an individual for two to three months; if the high intensity alveolitis persists, we then start therapy.
Where to from here? Undoubtedly, lavage and gallium-67 scanning will yield an enormous amount of new information concerning the interstitial lung diseases. Use of these methods have already shown that alveolitis is the key to these diseases and it is likely that both lavage and gallium-67 scanning will prove invaluable in making rational staging and therapy decisions. This is welcome news for a group of disorders that have previously been frustrating to the physician and often fatal to the patient. BRENDAN 
